Peptide LibraryResearch statistics
Rusfertide research: publications and trials
At a glance
Publications, all years
15
Since 2022
Publications in 2026 so far
5
Through November 1, 2026
Human clinical research
53.3%
8 of 15 classified
Registered clinical trials
10
ClinicalTrials.gov
Randomized controlled trials
6
Publications reporting an RCT in people
Systematic reviews and meta-analyses
0
Preclinical studies
0.0%
0 animal · 0 in vitro · 0 computational
Records that only mention it
5
Not counted above
Status in the library: FDA-approved.
What to keep in mind
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Rusfertide publications by year and evidence
Show the data
| Year | Human clinical research | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|
| 2022 | 0 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 0 | 1 |
| 2024 | 3 | 0 | 2 | 5 |
| 2025 | 3 | 0 | 0 | 3 |
| 2026 (to date) | 1 | 3 | 1 | 5 |
Study types
| Randomized controlled trial | 6 |
|---|---|
| Review | 4 |
| Editorial, letter or other | 3 |
| Other clinical trial | 2 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Antimicrobial and infectious disease | 5 |
|---|---|
| Metabolic health | 5 |
| Oncology | 5 |
| Cardiovascular | 3 |
| Immune system | 3 |
| Tissue repair | 2 |
| Endocrinology | 1 |
| Gastrointestinal | 1 |
Registered clinical trials
4 of 6 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 6 · Active, not recruiting: 2 · Not yet recruiting: 1 · Recruiting: 1
Phase 1: 1 · Phase 2: 7 · Phase 3: 2
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · October 13, 2026 · Randomized controlled trial · cited 0 times
PMID 42868322 · DOI 10.1200/jco-26-00992 · Human clinical research
- Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants.
Clinical therapeutics · September 30, 2025 · Randomized controlled trial · cited 2 times · open access
PMID 41033871 · DOI 10.1016/j.clinthera.2025.09.002 · Human clinical research
- Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.
Clinical pharmacology in drug development · January 29, 2025 · Randomized controlled trial · cited 4 times · open access
PMID 39888264 · DOI 10.1002/cpdd.1514 · Human clinical research
- Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Drugs in R&D · November 15, 2024 · Randomized controlled trial · cited 7 times · open access
PMID 39546273 · DOI 10.1007/s40268-024-00497-z · Human clinical research
- Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
European journal of haematology · May 24, 2024 · Randomized controlled trial · cited 11 times · open access
PMID 38785334 · DOI 10.1111/ejh.14243 · Human clinical research
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
The New England journal of medicine · February 1, 2024 · Randomized controlled trial · cited 58 times
PMID 38381675 · DOI 10.1056/nejmoa2308809 · Human clinical research
- Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.
Leukemia research · October 29, 2025 · Other clinical trial · cited 5 times · open access
PMID 41175501 · DOI 10.1016/j.leukres.2025.108132 · Human clinical research
- Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
The lancet. Gastroenterology & hepatology · October 17, 2023 · Other clinical trial · cited 41 times
PMID 37863080 · DOI 10.1016/s2468-1253(23)00250-9 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
The New England journal of medicine · February 1, 2024 · Randomized controlled trial · cited 58 times
PMID 38381675 · DOI 10.1056/nejmoa2308809 · Human clinical research
- Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial.
The lancet. Gastroenterology & hepatology · October 17, 2023 · Other clinical trial · cited 41 times
PMID 37863080 · DOI 10.1016/s2468-1253(23)00250-9 · Human clinical research
- Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.
Current opinion in hematology · December 29, 2022 · Review · cited 24 times · open access
PMID 36728649 · DOI 10.1097/moh.0000000000000747 · Reviews and meta-analyses
- Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
European journal of haematology · May 24, 2024 · Randomized controlled trial · cited 11 times · open access
PMID 38785334 · DOI 10.1111/ejh.14243 · Human clinical research
- Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Drugs in R&D · November 15, 2024 · Randomized controlled trial · cited 7 times · open access
PMID 39546273 · DOI 10.1007/s40268-024-00497-z · Human clinical research
Latest publications
- Rusfertide for the treatment of polycythemia vera.
Expert opinion on pharmacotherapy · October 31, 2026 · Review · cited 0 times
PMID 42958870 · DOI 10.1080/14656566.2026.2757984 · Reviews and meta-analyses
- Rusfertide for Polycythemia Vera: Incremental Benefit Assessment.
American journal of hematology · October 17, 2026 · Editorial, letter or other · cited 0 times · open access
PMID 42891571 · DOI 10.1002/ajh.70528 · Commentary and other
- VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · October 13, 2026 · Randomized controlled trial · cited 0 times
PMID 42868322 · DOI 10.1200/jco-26-00992 · Human clinical research
- Rusfertide
September 15, 2026 · Review · cited 0 times · open access
PMID 42766707 · Reviews and meta-analyses
- Targeting the hepcidin-ferroportin axis in polycythemia vera: a complementary approach to clone-directed therapies.
Blood reviews · August 26, 2026 · Review · cited 0 times
PMID 42660705 · DOI 10.1016/j.blre.2026.101420 · Reviews and meta-analyses
- Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera.
Leukemia research · October 29, 2025 · Other clinical trial · cited 5 times · open access
PMID 41175501 · DOI 10.1016/j.leukres.2025.108132 · Human clinical research
- Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants.
Clinical therapeutics · September 30, 2025 · Randomized controlled trial · cited 2 times · open access
PMID 41033871 · DOI 10.1016/j.clinthera.2025.09.002 · Human clinical research
- Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects.
Clinical pharmacology in drug development · January 29, 2025 · Randomized controlled trial · cited 4 times · open access
PMID 39888264 · DOI 10.1002/cpdd.1514 · Human clinical research
- Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers.
Drugs in R&D · November 15, 2024 · Randomized controlled trial · cited 7 times · open access
PMID 39546273 · DOI 10.1007/s40268-024-00497-z · Human clinical research
- Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
European journal of haematology · May 24, 2024 · Randomized controlled trial · cited 11 times · open access
PMID 38785334 · DOI 10.1111/ejh.14243 · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Mimrylo; PTG-300; Rusfertide; TAK-121
((TITLE_ABS:"Mimrylo" OR CHEM:"Mimrylo") OR (TITLE_ABS:"PTG-300" OR CHEM:"PTG-300" OR TITLE_ABS:"PTG300" OR CHEM:"PTG300") OR (TITLE_ABS:"Rusfertide" OR CHEM:"Rusfertide") OR (TITLE_ABS:"TAK-121" OR CHEM:"TAK-121" OR TITLE_ABS:"TAK121" OR CHEM:"TAK121")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 2). Rusfertide research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/rusfertide